1-3 of 3
Yuhong Ning
Close
Sort by
Journal Articles

Absence Of Mutation In Cereblon (CRBN) and DNA Damage Binding Protein 1 (DDB1) Genes In Myeloma Cells and Patients and Its Clinical Significance

Anjan Thakurta, PhD, Anita K Gandhi, PhD, Michelle Waldman, MS, Chad C. Bjorklund, Ph.D., Suzanne Lentzsch, MD, PhD, Stephen A Schey, MD, Yolanda Calle, PhD, Rajani Chelliah, BSc, MSc, Robert Z. Orlowski, M.D., Ph.D, Anup Madan, PhD, Yuhong Ning, Derek Mendy, B.S., Antonia Lopez-Girona, PhD, Peter H Schafer, PhD, Herve Avet-Loiseau, MD, Rajesh Chopra, MD
Journal: Blood
Blood (2013) 122 (21): 3139.
https://doi.org/10.1182/blood.V122.21.3139.3139
Published: 2013
Journal Articles

A Phase 1, Open-Label, Dose-Escalation Study to Evaluate the Safety, Pharmacokinetics, and Pharmacodynamics of Oral Azacitidine in Patients with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML).

Guillermo Garcia-Manero, MD, Steven D. Gore, MD, Barry Skikne, Christopher R. Cogle, MD, Yuhong Ning, Kyle J MacBeth, Eric Laille, M. Renee Ward, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 117.
https://doi.org/10.1182/blood.V114.22.117.117
Published: 2009
Journal Articles

A Comparative Pharmacokinetic/Pharmacodynamic (PK/PD) Evaluation of Azacitidine Following Subcutaneous (SC) and Oral Administration in Subjects with Myelodysplastic Syndromes (MDS) or Acute Myelogenous Leukemia (AML), Results From a Phase 1 Study.

Kyle J MacBeth, Eric Laille, Yuhong Ning, Christopher R. Cogle, MD, Barry Skikne, Steven D. Gore, MD, Guillermo Garcia-Manero, MD, M. Renee Ward, MD, PhD
Journal: Blood
Blood (2009) 114 (22): 1772.
https://doi.org/10.1182/blood.V114.22.1772.1772
Published: 2009